Bortezomib plus dexamethasone for relapsed or treatment refractory multiple myeloma: the collaborative study at six institutes in Kyoto and Osaka
详细信息 查看全文
- 作者：Tsutomu Kobayashi (1)
Junya Kuroda (1)
Kazuho Shimura (1) (2)
Teruaki Akaogi (3)
Eri Kawata (3)
Miki Kiyota (1) (3)
Takashi Tanaka (3)
Yuri Kamitsuji (4)
Satoshi Murakami (5)
Mayumi Hatsuse (5)
Akira Okano (5)
Toshiki Iwai (6)
Satomi Ueda (6)
Masahiko Koshida (6)
Hitoji Uchiyama (1)
Yosuke Matsumoto (1)
Hiroto Kaneko (2)
Nobuhiko Uoshima (4)
Yutaka Ueda (6)
Yutaka Kobayashi (3)
Chihiro Shimazaki (5)
Shigeo Horiike (1)
Masafumi Taniwaki (1) - 关键词：Bortezomib ; Multiple myeloma ; Relapse
- 刊名：International Journal of Hematology
- 出版年：2010
- 出版时间：November 2010
- 年：2010
- 卷：92
- 期：4
- 页码：579-586
- 全文大小：327KB
- 参考文献：1. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516-0. CrossRef
2. Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111:2962-2. CrossRef
3. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487-8. CrossRef
4. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007;110:3557-0. CrossRef
5. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. Extended follow-up of phase II trial in relapsed, refractory multiple myeloma. Final time-to-event results from the SUMMIT trial. Cancer. 2006;106:1316-. CrossRef
6. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol. 2007;137:429-5. CrossRef
7. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapse, refractory myeloma. N Engl J Med. 2003;348:2609-7. CrossRef
8. Jagannath S, Durie BG, Wolf JL, Camacho ES, Irwin D, Lutzky J, et al. Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma. Br J Haematol. 2009;146:619-6. CrossRef
9. Jagannath S, Barlogie B, Berenson JR, Siegel DS, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Esseltine DL, Anderson KC. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol. 2008;143:537-0.
10. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood. 2005;106:2977-1. CrossRef
11. Orlowski RZ, Nagler A, Sonneveld P, Blade J, Hajek R, Spencer A, et al. Randomised phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25:3892-01. CrossRef
12. Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood. 2008;112:1593-. CrossRef
13. Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau J, et al. Reversiblity of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of dose-modification guideline. Br J Haematol. 2009;144:895-03. CrossRef
14. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467-3. CrossRef
15. Gotoh A, Ohyashiki K, Oshimi K, Usui N, Hotta T, Dan K, et al. Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan; a questionnaire-based report from the “lung injury by bortezomib-joint committee of the Japanese society of haematology and the Japanese society of clinical haematology. Int J Hematol. 2006;84:406-2. CrossRef
16. Miyakoshi S, Kami M, Yuji K, Matsumura T, Takatoku M, Sasaki M, et al. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood. 2006;107:3492-. CrossRef
17. Jagannath S, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia. 2007;21:151-. CrossRef
18. Vogl DT, Stadtmauer EA, Richardson PG, Sonneveld P, Schuster MW, Irwin D, et al. Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma. Br J Haematol. 2009;147:531-. CrossRef
19. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354:1021-0. CrossRef
20. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, et al. A phase 2 study or two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004;127:165-2. CrossRef
21. Ohguchi H, Sugawara T, Ishikawa I, Okuda M, Tomiya Y, Yamamoto J, et al. A retrospective analysis of bortezomib therapy for Japanese patients with relapsed or refractory multiple myeloma: beta2-microglobulin associated with time to progression. Int J Hematol. 2009;89:342-. CrossRef - 作者单位：Tsutomu Kobayashi (1)
Junya Kuroda (1)
Kazuho Shimura (1) (2)
Teruaki Akaogi (3)
Eri Kawata (3)
Miki Kiyota (1) (3)
Takashi Tanaka (3)
Yuri Kamitsuji (4)
Satoshi Murakami (5)
Mayumi Hatsuse (5)
Akira Okano (5)
Toshiki Iwai (6)
Satomi Ueda (6)
Masahiko Koshida (6)
Hitoji Uchiyama (1)
Yosuke Matsumoto (1)
Hiroto Kaneko (2)
Nobuhiko Uoshima (4)
Yutaka Ueda (6)
Yutaka Kobayashi (3)
Chihiro Shimazaki (5)
Shigeo Horiike (1)
Masafumi Taniwaki (1)
1. Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, 465, Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan
2. Department of Hematology, Aiseikai Yamashina Hospital, Kyoto, Japan
3. Department of Hematology, Kyoto Second Red Cross Hospital, Kyoto, Japan
4. Department of Hematology, Matsushita Memorial Hospital, Osaka, Japan
5. Department of Hematology, Kyoto Social Insurance Hospital, Kyoto, Japan
6. Department of Hematology, Kyoto First Red Cross Hospital, Kyoto, Japan
文摘
We conducted a retrospective collaborative investigation of bortezomib (Bor) plus dexamethasone (Dex) therapy (BD Tx) for 88 relapsed or refractory (Rel/Ref) MM patients at six institutes. One cycle BD Tx comprised of Bor (1.3?mg/m2/day) on days 1, 4, 8 and 11, and Dex on days 1, 2, 4, 5, 8, 9, 11 and 12, every 21?days, and the mean number of BD Tx cycles was 3. The overall response rate was 66.9%, the median overall survival (OS) was 510?days, and the median progression-free survival (PFS) was 113?days. Attainment of partial response (PR) with the first course of BD Tx associated with the longer OS and PFS and late good responder, while no patient who did not achieve PR with the first cycle attained better than very good PR (VGPR) with the subsequent BD Tx. Patient age of less than 64?years old also associated with the longer OS and PFS. In addition, both an earlier disease stage and Dex dosage had a significant impact on OS, while the attainment of VGPR within 2 cycles had a significantly longer PFS. Earlier BD Tx courses may be predictive for the subsequent therapeutic pathway of Rel/Ref MM.